Abstract
Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells.
Publication types
-
Clinical Trial, Phase II
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Female
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use*
-
Janus Kinase 2
-
Male
-
Middle Aged
-
Mutation
-
Myeloproliferative Disorders / drug therapy*
-
Myeloproliferative Disorders / enzymology
-
Myeloproliferative Disorders / genetics*
-
Polycythemia Vera / drug therapy
-
Polycythemia Vera / enzymology
-
Polycythemia Vera / genetics
-
Polyethylene Glycols
-
Protein-Tyrosine Kinases / genetics*
-
Proto-Oncogene Proteins / genetics*
-
Recombinant Proteins
-
Thrombocythemia, Essential / drug therapy
-
Thrombocythemia, Essential / enzymology
-
Thrombocythemia, Essential / genetics
-
Treatment Outcome
Substances
-
Interferon alpha-2
-
Interferon-alpha
-
Proto-Oncogene Proteins
-
Recombinant Proteins
-
Polyethylene Glycols
-
Protein-Tyrosine Kinases
-
JAK2 protein, human
-
Janus Kinase 2
-
peginterferon alfa-2b